WallStSmart
THRD

Third Harmonic Bio Inc.

NASDAQ: THRD · HEALTHCARE · BIOTECHNOLOGY

$5.38
+0.00% today

Updated 2026-06-05

Market cap
$242.79M
P/E ratio
P/S ratio
EPS (TTM)
$-1.24
Dividend yield
52W range
$5 – $6
Volume

Third Harmonic Bio Inc. (THRD) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item20202021202220232024
Total assets$8.43M$129.16M$298.68M$277.71M$294.61M
Cash & equivalents$8.28M$128.28M$288.88M$269.07M$285.06M
Current assets$8.43M$129.16M$292.83M$272.45M$290.54M
Total liabilities$26.79M$175.87M$9.61M$8.63M$9.46M
Current liabilities$2.21M$5.69M$5.65M$5.42M$7.11M
Long-term debt
Shareholder equity$342000.00$123.48M$289.07M$269.08M$285.15M
Retained earnings$-18.63M$-48.24M$-83.40M$-114.22M$-159.69M
Accounts receivable
Inventory
Goodwill

Frequently asked questions

How much free cash flow does THRD generate?

THRD produced $-34.51M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is THRD's balance sheet healthy?

THRD holds $285.06M in cash and equivalents against — in long-term debt, on $285.15M of shareholder equity. That debt is best read against the cash flow the business throws off each year.